奥曲肽对胃癌术后血中VEGF及肠功能的影响
 |
| 第1页 |
参见附件。
【摘要】目的 探讨奥曲肽对胃癌术后VEGF及肠功能的影响。方法 选择我院胃癌术后患者86例，将上述患者随机分为观察组和对照组各43例，正常健康对照组为正常体检者18例。两组患者均给予常规治疗。对照组患者患者术后不给任何刺激肠蠕动的药物；观察组患者给予奥曲肽，初次剂量为0.1mg，静脉注射，而后0.2~0.4mg 加入250mL 生理盐水中静脉24h持续滴注，3次/d，连续应用3~6d。正常健康对照组体检时、两组患者均于术后第二天及术后第7天空腹抽血5ml, 采用ELISA法定量检测VEGF。结果 胃肠功能恢复情况，观察组优于对照组(P>0.01)；术后2天、7天VEGF水平两组均高于正常对照组(P>0.01)；术后7天VEGF水平均下降，观察组下降明显与对照组(P>0.01)。结论 奥曲肽能够显著提高胃癌术后患者VEGF，能够显著改善胃癌术后的胃肠动力，临床效果显著。
【关键词】胃癌 ； 血管内皮生长因子；奥曲肽 ；胃肠动力
Octreotide on gastric cancer after blood and intestinal function of VEGFShunan,Ousanji,Penxiaohui
Shi Nan OuShanji PenXiaohiu
【Abstract】 ObjectiveTo investigate the effects of octreotide on gastric cancer and intestinal function of VEGF. Methods hospital patients with gastric cancer, 86 cases of the above were randomly divided into two groups and the control group, 43 cases of normal healthy control group of normal physical examination in 18 cases. All patients received conventional therapy.Control group patients were not given any drugs to stimulate bowel movements; observation group were treated with octreotide, the initial dose of 0.1mg, intravenous injection, then 0.2 ~ 0.4mg adding 250mL 24h continuous infusion of intravenous normal saline, 3 times / d continuous application of3 ~ 6d. Normal healthy control group, physical examination, patients in both groups at postoperative day and 7 days after the fasting blood 5ml, using ELISA for quantification of VEGF. Results of the recovery of gastrointestinal function, the observation group than the control group (P>0.01); after 2 days, 7 days in both groups VEGF levels higher than the normal control group (P>0.01); 7 days after VEGF levels were decreased the observation group decreased significantly compared with the control group (P>0.01). ConclusionOctreotide significantly increased gastric cancer patients VEGF, can significantly improve gastric cancer of gastrointestinal motility, a significant clinical effect.
【Key words】Gastric cancer; vascular endothelial growth factor; octreotide; gastrointestinal motility
【中图分类号】R362 【文献标识码】B 【文章编号】1005-0515(2011)07-0274-02
胃癌是我国常见的恶性肿瘤， 其手术时机基本已到晚期，手术损伤较大，术后肠功能恢复较差。血管内皮生长因子[1] (vascular endothelial growth factor，VEGF) )在胃癌组织中高表达， 对胃癌新生血管形成及肿瘤生长和转移起重要作用，已得到证实。其术后在肠功能恢复过程是否有变化如何，则鲜有报道。本研究奥曲肽对胃癌术后VEGF的变化及肠功能的影响，现报道如下。
1材料与方法
1.1 临床材料 均来我科2008年7月至2009年19月住院治疗胃癌患者，其中男性68例 ， 女性18例；年龄26~67岁，平均35.7±12.5岁；均接受根治性手术治疗，术前均经胃镜组织病理诊断为胃癌，术后病理组织学分型：高/中分化42例，低分化44例；浸润深度达肌层者26例，达浆膜层者60例；有淋巴结转移者68例，无淋巴结转移者18例。随机分为观察组和对照组各43例，两组患者年龄、性别、术后病理诊断差异均无统计学意义。正常对照组来自本院体检中心健康体检者，男性10名，女性8名；年龄24 ~71岁，平均34.1±13.4岁，与其他入选病人间无亲缘关系。健康志愿者同胃癌患者年龄、性别差异无统计学意义。
1.2治疗方法两组患者均给予常规治疗。对照组患者患者术后不给任何刺激肠蠕动的药物；观察组患者给予奥曲肽，初次剂量为0.1mg，静脉注射，而后0.2~0.4mg 加入250mL 生理盐水中静脉24h持续滴注，3次/d，连续应用3~6d。
1.3检测方法 人VEGF酶联免疫吸附试验(ELISA)试剂盒(武汉博士生物有限公司)。正常健康对照组体检时、两组患者均于术后第二天及术后第7天空腹抽血5ml, 采用ELISA法定量检测SLE。严格按说明书操作，通过绘制标准曲线求出标本中VEGF浓度 ......
您现在查看是摘要介绍页，详见PDF附件(2733kb)。